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Purpose: To develop a self-administered questionnaire assessing patients’ satisfaction with 
treatments in Crohn’s disease for use in clinical research and epidemiological studies.
Patients and methods: Semi-directive interviews (16) were conducted with patients with 
severe Crohn’s disease treated with anti-tumor necrosis factor alpha (anti-TNFα). Transcripts 
were analyzed and concepts related to satisfaction with treatment were extracted and organized 
into a model. Items were generated using patients’ words. The resulting test version was tested 
for relevance and comprehension with 7 patients and revised accordingly; the new version was 
tested with 5 other patients and revised to provide the pilot version. A clinician advisory board 
was involved at each milestone of the development.
Results: The test questionnaire assessed treatment satisfaction through 67 items, organized into 
5 sections: treatment efficacy, side-effects, convenience and constraints, overall impact, and 
satisfaction. Conceptual content of the questionnaire includes comparison with prior state and 
with expectations, satisfaction, acceptability, and intentions. The questionnaire was generally 
well accepted and understood by patients; few modifications were made in the structure and item 
formulation. After the second round of comprehension tests, the pilot version contained 62 items; 
the questionnaire was named Satisfaction of PAtients in Crohn’s diseasE (SPACE©).
Conclusion: The questionnaire is a unique tool to assess treatment satisfaction in patients with 
Crohn’s disease. A scoring and validation study is currently being performed to finalize and 
establish its scoring, as well as its psychometric properties.
Keywords: Crohn’s disease, anti-TNF treatment, questionnaire, patient satisfaction, patient-
reported outcome
Introduction
Crohn’s disease (CD) is an idiopathic, chronic, inflammatory disease of the 
gastrointestinal tract characterized by intermittent flares. Typical manifestations of CD 
include diarrhea, abdominal pain, weight loss, rectal bleeding, and fever,1 and can lead 
to complications such as strictures, abscesses, and fistulae.2 The growing importance 
of this disease and its debilitating nature explain the need for efficient treatments to 
limit its impact on patients’ lives.
Conventional CD treatments include 5-aminosalicylates, corticosteroids, and 
immunosuppressant treatments,3 and more recently the anti-tumor necrosis factors 
alpha (anti-TNFα) such as infliximab or adalimumab.3 Anti-TNFα have shown good 
efficacy over the past years in the induction and maintenance of remission in CD.4,5 
They represent a considerable advance in CD management,6 improving both the 
clinical aspects of the disease and the patients’ health-related quality of life (HRQL).4,7,8 Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Even though CD therapies have similar efficacy and safety 
profiles,4,6 they differ in terms of mode and constraints of 
administration, leading to different convenience profiles.6
As the peak period for the onset of CD is in the second 
and third decades of life,9 many patients with CD are young 
adults. Perception of treatment and its constraints, as well 
as satisfaction with treatment, may thus play a particularly 
critical role in the management of CD. For example in a recent 
study, 40% of patients with CD aged 40 years on average 
described the treatment as moderate or bad.10
To investigate patients’ satisfaction with their medication 
is of relevance in order to improve and adapt their pharma-
cological management, and to help to improve adherence to 
treatment.11 Patient perspective and more largely qualitative 
research are acknowledged and essential in the field of CD.12,13 
Quality-of-life studies were performed in inflammatory 
bowel diseases,8,14–17 in clinical trials, HRQL was used as 
a secondary endpoint.12 However, no study has assessed 
patients’ satisfaction in CD.10 A recent prospective study 
showed that despite the preference of CD patients for adali-
mumab versus infliximab for maintenance, a proportion of 
patients returned to infliximab due to intolerance, supporting 
the importance of patients’ outcomes in patients’ behavior 
towards CD’s therapeutics and their efficacy.18
Satisfaction is defined as an emotive evaluation which 
enables the assessment of the appropriateness of the perceived 
quality of treatment with expectations.19 Satisfaction is 
different from HRQL, which covers physical, psychological, 
social functioning, and somatic sensations.20 For this reason, 
instruments developed to measure HRQL cannot be used to 
assess patients’ satisfaction with their treatment. Satisfaction 
with medication, as defined by Shikiar and Rentz, is “the 
patient’s evaluation of the process of taking the medication 
and the outcomes associated with the medication”.21 This is 
thus a specific subdimension of treatment satisfaction, which 
encompasses both medicinal and nonmedicinal aspects of 
treatment (eg, relationship with physician). In our work, we 
explored specifically satisfaction with medication.
To our knowledge, no specific instruments exist that 
assess patients’ satisfaction with anti-TNFα therapeutics. 
Those questionnaires used in the field of CD either do not 
evaluate satisfaction with anti-TNFα treatments specifically 
and are not designed to be used with severe CD condition, 
such as the Treatment Satisfaction Questionnaire for Crohn’s 
disease (TSQ-C);29 or are specific to CD treatments but 
assess HRQL rather than patients’ satisfaction, such as the 
Inflammatory Bowel Disease Questionnaire and the Rating 
Form of Inflammatory Bowel Disease Patient Concerns.12,22 
Other available instruments such as the   Treatment Satisfaction 
Questionnaire for Medication (TSQM) and the Treatment 
Satisfaction with Medicines Questionnaire (SATMED-Q) 
are generic satisfaction questionnaires.23
Our aim was to develop a specific self-administered 
questionnaire to assess patients’ satisfaction with anti-TNFα 
treatments in CD for use in clinical research studies and 
epidemiological studies. This paper focuses on the qualitative 
steps of the questionnaire development with respect to the 
current methodological standards.24
Materials and method
Clinical advisory board
A clinical advisory board composed of 7 clinicians 
experienced in the field of CD management, working either 
at hospital, in secondary care, or at university, was set up at 
the beginning of the study.
The role of the clinical advisory board was to provide 
clinical expertise throughout questionnaire development and 
to ensure its clinical relevance, to validate study   documents 
and decisions made at each milestone, and to review the 
questionnaire.
Exploratory phase: literature review
A literature review was carried out to identify existing 
  questionnaires assessing patient satisfaction with CD 
treatments or with anti-TNFα treatments. Search was 
conducted in biomedical databases (Embase, MEDLINE) 
from 2005 to 2008, the patient-reported outcomes and quality 
of life instruments database (ProQolid), as well as abstracts 
from patient-reported outcomes conferences (International 
Society for Quality of Life Research, International Society 
for Pharmacoeconomics and Outcomes Research) from 2005 
to 2007 and from gastroenterology conferences (United 
European Gastroenterology Week 2006 and 2007, European 
Crohn’s disease and Colitis Organisation from 2006 to 2008). 
Abstracts were selected if they included information on 
patients treated with anti-TNFα treatments or if they involved 
patients with CD or inflammatory bowel disease reporting 
their satisfaction or preference.
Development of the conceptual  
model of the questionnaire
All the patients gave their informed consent to participate 
in the study.
In order to help define inclusion criteria and content for 
the second set of patient interviews, 3 patient interviews were 
performed to gather patients’ perception and experience of Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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anti-TNFα treatments in CD. Gastroenterologists recruited 
voluntary male and female patients diagnosed with CD and 
treated either with infliximab or adalimumab for at least 
3 months. Interviews were conducted face-to-face using 
exploratory questions on treatment: expectations, satisfac-
tion, perceived constraints, efficacy and side-effects, impacts 
of treatment.
Based on information retrieved during this first set of 
patient interviews, a specific interview guide was developed 
to carry out a second set of 13 exploratory patient interviews 
in order: 1) to gather information on patient   experience with 
anti-TNFα treatments in CD and their impact on every day 
life; 2) to gather patients’ words to develop the items of 
the questionnaire. The second set of patients (n = 13) was 
recruited by 6 gastroenterologists. Patients had been diagnosed 
with CD for at least 2 years, having been treated either with 
infliximab or adalimumab for at least 6 months, and treated 
with corticosteroids at least once for their CD. A psychologist 
performed the exploratory   face-to-face interviews using a 
semi-directive interview method. The aim of this approach 
was to offer speaking time to interviewees by means of 
open questions, to enable patients express their perception 
of the advantages and disadvantages of their anti-TNFα 
treatments.25
The 13 exploratory interviews were analyzed using a 
thematic approach. The significant elements of patients’ speech 
expressing concepts directly or indirectly related to patient 
satisfaction with their anti-TNFα treatments were extracted: 
experience related to satisfaction, comparison between previ-
ous expectations and real experience leading to satisfaction, 
satisfaction as such, or expressed in terms of acceptability or 
intentions. Concepts related to quality of life or disease impact 
were not extracted, as they were not related to satisfaction 
with medication. At this stage, a detailed   conceptual model 
of patients’ satisfaction was   developed and agreed on during a 
meeting with the clinical advisory board and patient-reported 
outcomes experts. Concepts to be measured in the future 
questionnaire were selected at that step, based on their clinical 
relevance (according to the clinical advisory board members), 
and their importance from a patient perspective (according to 
the team who participated in the patients’ interview conduct 
and analysis).
Development of the pilot version  
of the questionnaire
item generation
Based on the identified concepts related to patients’ satisfac-
tion that had to be assessed, the team involved in conducting 
and analyzing the exploratory phase and patient interviews 
generated items in French using patients’ own words to 
provide the first test version of the questionnaire.
Comprehension tests
The content validity of the questionnaire was tested dur-
ing comprehension interviews to check the acceptability 
and relevance of the questionnaire for patients with CD. 
Ten patients were recruited by gastroenterologists according 
to the same inclusion criteria as for the second set of patient 
exploratory interviews; 2 other patients were recruited if they 
had been diagnosed with CD for at least 2 years, and if they 
were treated with corticosteroids. A psychologist conducted 
face-to-face interviews. Patients were asked to comment on 
their understanding of each item and to suggest alternative 
formulations in the case of problematic wording. The com-
prehension test methodology followed an iterative process: 
a first set of 7 patients was interviewed, modifications were 
made to the questionnaire according to the patients’ sugges-
tions, and the resulting version was tested during interviews 
with 5 other patients, following the same methodology.
Pilot version
After analysis of the second set of interviews and last modi-
fications made to the second test version, the pilot version 
of the questionnaire was issued in French.
Results
Exploratory phase: literature review
Four questionnaires assessing patient satisfaction with CD 
treatments or with anti-TNFα treatments were retrieved from 
the literature review: 1) a questionnaire developed by Chilton   
and Collett in 2008, assessing preferences of patients with 
rheumatoid arthritis (RA) with 3 treatment options;26 2) the 
Self-Injection Assessment Questionnaire (SIAQ), developed in 
2007, assessing the perceived advantages of self-injection and 
potential limitations of self-injection in RA and CD;27 3) a spe-
cific questionnaire developed by Kivitz et al in 2006, assessing 
preference of patients with RA between 2 treatment devices;28 
and 4) the TSQ-C developed in 2005, assessing the satisfaction 
with pharmacological therapy in patients with mild to moderate 
CD.29 However, none of them aimed at evaluating specifically 
patients’ satisfaction with anti-TNFα treatments in CD.
Development of the conceptual  
model of the questionnaire
The first 3 patient interviews confirmed the feasibility of 
the qualitative approach, as well as the relevance of the con-Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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cept of satisfaction to be explored. Their analysis identified 
areas of interest in severe CD treated with anti-TNFα. 
These themes were further explored with the second set of 
13 patients: experience of both past and current treatments, 
ie, efficacy, side-effects, and perception of constraints of 
treatment, as well as impact of these treatments and overall 
satisfaction. Table 1 summarizes sociodemographic and 
clinical characteristics of the patients interviewed during the 
exploratory phase. Age and level of education of each group 
was represented through the 13 interviewed patients, and the 
majority were professionally active. The median disease dura-
tion was 6 years, and the majority of the patients were treated 
with infliximab (8 out of the 13; the remaining 5 were treated 
with adalimumab) (Table 1).
A total of 595 concepts and subconcepts were extracted 
from the patient interviews. Their thematic analysis revealed 
6 main groups of concepts directly or indirectly related to 
patient satisfaction with anti-TNFα treatments: efficacy 
(eg “I feel much more better”), side-effects (eg “There 
is always an unpleasant effect”), convenience (eg “I can 
do it in my room as well as I can in my kitchen”), mode 
of administration (eg “What I like are the little pencils”), 
treatment impact (eg “I’m full of energy again”), and overall 
satisfaction (eg “I’m happy with it”). The different treatment 
attributes were all expressed in terms of experience, and 
compared with previous expectations to form a satisfaction 
evaluation. The detailed concepts corresponding to 
these groups of concepts were further discussed with 
the clinical advisory board: 5 global concepts and 41 
corresponding detailed concepts were selected and agreed 
on for   measurement using the future questionnaire. General 
concepts covered efficacy, side-effects, convenience and 
constraints (including the previous “mode of administration” 
general concept), overall impact, and satisfaction.
Development of the pilot version  
of the questionnaire
item generation
Item generation resulted in the first test version of the 
questionnaire containing 57 items in French organized into 
5 dimensions: efficacy (16 items), side-effects (7 items), 
convenience and constraints (13 items), overall impact 
(8 items), and satisfaction (13 items). Answer choices were 
4- and 5-point Likert-like scales. For questions on symptoms   
(6 items), each item was divided into 2 questions: the first one 
assesses whether the symptom was present in the past using 
a dichotomic answer choice; in the case of a positive answer,   
Table 1 Patient characteristics: exploratory and comprehension 
test interviews
Patients’  
characteristics
Exploratory  
interviews n = 13
Comprehension   
tests n = 12
Gender (N)
  Male 4 7
  Female 9 5
Age
    Median (minimum- 
maximum) (years)
29 (21–74) 43 (25–62)
  18–25 years (n) 4 1
  26–40 years (n) 5 4
  $41 years (n) 4 7
Familial status (N)
  Living with partner 13 8
  Living alone 0 3
  Widowed 0 1
Level of education (N)
    General certificate of 
secondary education
3 5
  A-levels 3 1
    Undergraduate degree 
or national vocational 
qualification
1 4
    Graduate degree  
or 4-year degree
6 2
Professional status (N)
  Working full-time 7 5
  Working part-time 2 3
  Unemployed 0 1
  student 0 1
    housewife or  
househusband
2 0
  retired 2 2
Disease duration (years)
    Median  
(minimum-maximum)
6 (3–24) 42 (6–21)
Anoperineal form (N) 6 5
Surgery related  
to Crohn’s disease (N)
5 6
Current treatment (N)
  5-amino salicylic acid 2 1
  Corticosteroids 3 3
    immunosuppressant  
agents
9 1
Anti-TNFα
  Infliximab 8 4
    Switch infliximab to 
adalimumab
5 6
the second one assesses how the medication has been 
  effective on the symptom using a Likert-like scale.
Comprehension tests
Each age group and level of education were represented 
among the 12 patients who participated in the comprehension Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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tests (Table 1). During the first set of comprehension tests, 
the 7 patients found the questionnaire easy to understand, 
easy to answer, and well formatted. Based on patients’ 
suggestions, 4 questions corresponding to 4 new detailed 
concepts were added (intensity of attacks, speed of effi-
cacy on attacks, work organization, and organization with 
children) and 1 was removed (side-effects) due to group-
ing of 2 questions; 13 items were slightly reformulated to   
improve patients’ understanding; and a few modifications were 
made on format and structure of the questionnaire to provide 
the second test version containing 60 items organized into   
the same sections as the first test version. Based on the second 
set of 5 patients’ suggestions, 2 questions corresponding to 
2 new detailed concepts were added (efficacy of relief from 
attacks, reassuring mode of administration), and minor modi-
fications similar to those made on the first test version were 
made on the second test version to provide the pilot version 
of the questionnaire.
Pilot version
Finally, the pilot version of the questionnaire contained 62 
items organized into the same 5 dimensions as the test versions: 
efficacy (19 items), side-effects (6 items), convenience and 
constraints (16 items), overall impact (8 items), and satisfac-
tion (12 items). The questionnaire ends with an open-ended 
question on patients’ expectations of a potential future treat-
ment. The detailed item content of the pilot questionnaire is 
presented in Table 2. Among the 62 items, 45 are defined 
as “factual” questions (eg, “With my current treatment, my 
disease is stabilized”), and the 17 remaining are defined as 
“evaluation” questions (eg, “Today, are you satisfied with the 
efficacy of your treatment?”). These “evaluation” questions 
are related to comparison with expectations, acceptability, 
and overall satisfaction. The questionnaire is to be filled out 
by the patients at study visits; time for completion should be 
about 10 to 15 minutes.
As the questionnaire is intended to measure patients’ 
satisfaction with treatments in CD, the questionnaire was 
called SPACE© questionnaire (Satisfaction of PAtients with 
Crohn’s disease). The pilot version of SPACE© is currently 
being validated.
Discussion
In the past 5 years, anti-TNFα has become a cornerstone in 
the management of CD refractory to conventional treatment 
algorithms.30 Randomized controlled trials have shown their 
efficacy for active CD;3,4 several studies demonstrated that 
Table 2 Pilot questionnaire version item content (concepts and 
detailed concepts measured by dimension)a
Dimensions  
(no. items)
Item content
Efficacy  
(19 items)
Psychological well-being 
Physical well-being 
speed of improvement 
health state stabilization 
Overall well-being (2 items) 
Crohn’s attacks (4 items: frequency,  
intensity, efficacy, speed of efficacy) 
Diarrhea 
Abdominal pain 
incontrollable need to defecate 
Anal pain 
Anal leakage 
Diet 
Protection against symptoms 
Protection against surgery 
Comparison to expectations
side-effects  
(6 items)
information 
Bother 
Worries 
Pregnancy 
Comparison to expectations 
Acceptability
Convenience and  
constraints (16 items)
Mode of administration (7 items): type,  
practical, constraining, unpleasant,  
reassuring, worrisome, easy 
Organization constraints (7 items): travel, 
medical appointments, time, costs,  
conservation, work, children 
Comparison to expectations 
Acceptability
Overall impact  
(8 items)
impact on mood 
impact on energy 
impact on physical status 
impact on emotions in relationships 
impact on professional life 
impact on family life 
impact on social life 
Overall impact on life
satisfaction  
(12 items)
Efficacy on Crohn’s attacks 
side-effects 
Organization constraints 
Mood 
Energy 
Physical status 
Emotions in relationships 
Family life 
Professional life 
social life 
Motivation to continue taking  
treatment 
Overall evaluation
Expectations  
(1 item)
Expectations toward new treatment
Notes: aitem content presented in this table was translated into English, but did not 
follow a linguistic validation process at this stage.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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HRQL of patients with CD treated with anti-TNFα was 
improved.7,8,17 Nevertheless, the burden of these   treatments’ 
administration should be considered when choosing among 
different anti-TNFα medications. Perception of the different 
constraints of administration and other attributes of treatment 
(efficacy, side-effects) can widely differ among patients; these 
differences in patients’ perceptions can be captured through 
the assessment of patient satisfaction with medication.
Research has widely focused on the pathophysiology and 
management of the disease. Some studies assessed patients’ 
perceptions on benefits and risks of anti-TNF treatments,31,32 
but to our knowledge, satisfaction with treatment has been 
poorly reported in the literature.10 The SPACE© questionnaire 
is thus the first tool to assess patient satisfaction with 
  anti-TNFα treatment in CD. Even though focused on anti-
TNFα treatment, the profile of patients who have been 
involved in the design of the questionnaire should allow its 
wider use to a population of patients treated with alternative 
Crohn’s disease treatment that are the corticosteroids. One of 
the challenges when   developing a questionnaire is to specifi-
cally address its defined topic and purpose. That is the reason 
why interviews were   carried out using   specific interview 
guides; this   provided a framework to obtain feedback of 
their experience and perception of their   treatment. Prior to 
item generation, a selection   process involving both clini-
cal and patient-reported   outcomes experts was applied to 
select appropriate concepts and detailed concepts relevant 
to the purpose of the study. During patient interview analy-
sis, concepts and detailed concepts were extracted if they 
  corresponded to the central concept of satisfaction as such; if 
they corresponded to one of the determinants of satisfaction, 
ie, experience, either or not compared with previous expecta-
tions; or if they corresponded to the result of the satisfaction 
process, ie, acceptability or intentions of behavior. This 
ensured that the concepts to be measured in the questionnaire 
corresponded to one of the elements belonging to satisfaction 
models.11,19,21 Moreover, as all these concepts have been dis-
cussed domain by domain with the clinical advisory board 
before detailed concept selection, it is expected that there is 
no bias in the selection of concepts to be measured. Through 
its 62 items, the developed questionnaire assesses patients’ 
satisfaction with concepts that are   important for treatment 
evaluation. Moreover, the questionnaire is composed of 
both “factual” and “evaluation” questions, with “factual 
  questions” expected to favor reliable and valuable answers 
to the evaluation questions. A short form of the questionnaire 
including only evaluating questions could be envisaged for 
future use.
Another challenge in the development of questionnaires 
is to ensure the reproducibility of the work. The SPACE© 
questionnaire was developed following a well-established 
qualitative methodology involving predefined objectives and 
hypothesis on satisfaction with anti-TNFα treatment in CD, 
which should ensure the reproducibility of the results.21,24 The 
first set of 3 patient interviews confirmed the applicability 
of the thematic approach; moreover, the involvement of the 
clinical advisory board at each milestone of questionnaire 
development (patient inclusion criteria, choice of concepts 
to be measured, and validation of modifications) ascertained 
the clinical relevance and the consolidation of the results. 
To ensure item appropriateness, specific attention was 
paid to ensure that patients included in the questionnaire 
development corresponded to those patients targeted for 
future use of the questionnaire, ie, patients with CD treated 
either with anti-TNFα or corticosteroids. Two comprehension 
tests were thus realized with patients treated with corticos-
teroids. The usefulness of qualitative research has already 
been recognized in the field of inflammatory bowel diseas-
es.13 Following this rigorous methodology while developing 
the SPACE© questionnaire allows patient perspective to be 
adequately captured.
One limitation that should be noted at this stage is the 
absence of a formal saturation process.33 However, it was 
noted when analyzing the second set of patient interviews 
that the analysis of the last 2 interviews did not reveal any 
additional concepts related to satisfaction with treatment 
compared to the content of the first 11 interviews. Moreover, 
interviews of 3 experienced nurses and 3 gastroenterologists 
in a preliminary phase supported the identified concepts 
and did not show any additional concepts compared with 
those of the exploratory patient interviews (data not shown). 
In addition to the participation of the clinical advisory board 
in the choice of concepts to be measured, this guaranteed the 
comprehensiveness of the   conceptual content of the SPACE© 
questionnaire, both from the patient and clinical perspective. 
Finally, the comprehension tests carried out with patients 
confirmed the relevance of the questionnaire content in the 
context of CD treated with anti-TNFα or corticosteroids; they 
also improved overall comprehension of the questionnaire 
and guaranteed acceptability thanks to the iterative process 
used. One could also argue the French nature of the study as 
another limitation of the questionnaire as other cultures might 
not consider the same attributes to define their satisfaction 
with anti-TNFα treatments. In case the questionnaire is to 
be used in non-French studies, it will need to be validated 
in this country.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Other questionnaires evaluating satisfaction with 
treatments are used in the field of CD. Among these, TSQ-C 
is a disease-specific questionnaire evaluating patients’ 
  satisfaction with pharmacological treatment in CD.29 How-
ever, this questionnaire aims at evaluating satisfaction of 
patients with mild to moderate CD, thus considering treat-
ments that differ from anti-TNFα prescribed in more severe 
CD. It also measures concepts different from satisfaction 
with medication itself (eg, satisfaction with their relation-
ships with their physician or preference between different 
treatments). Moreover, the TSQ-C was developed from a 
gastroesophageal reflux disease-specific questionnaire by 
item reduction, without involving patients in its qualitative 
development process.
TSQM and SATMED-Q are 2 other satisfaction 
  questionnaires used to assess patient satisfaction with 
treatment in various areas, including CD. The TSQM was 
designed to measure patients’ satisfaction with different 
types of medication and with different types of patient 
populations,23 whereas the SATMED-Q was developed to be 
used in chronic patients undergoing pharmacological treat-
ment for any disease.34 The first questionnaire assesses effec-
tiveness, side-effects, convenience, and overall satisfaction 
with treatment, and the second assesses the same domains 
with additional questions on the effect on daily activities, and 
patient satisfaction with medical care. However, both these 
satisfaction questionnaires are a generic measure of patient 
satisfaction and do not specifically assess patient satisfac-
tion with anti-TNFα in severe CD, as does the SPACE© 
questionnaire.
Numerous studies have shown the relationship between 
patients’ satisfaction and treatment compliance, or at least 
intentions to or persistence in taking medications.23,34–38 It can 
thus be expected that satisfaction with medication is related to 
patient adherence to prescription regimens.21 As the adverse 
decisional consequences of low treatment satisfaction on 
medication compliance is of particular concern to caregivers 
treating patients with chronic conditions,11 measuring patient 
satisfaction with medication is of particular interest in severe 
CD to assess treatment benefits, or to understand the needs 
and expectations of patients.
The SPACE© questionnaire has been translated into French 
for Canada, English for Canada, Greek, and Portuguese 
  following a backward and forward standard linguistic valida-
tion process.39 This will facilitate its use in international stud-
ies. The SPACE© questionnaire is currently being validated in 
a multicenter, longitudinal, noninterventional observational 
study in patients with severe CD treated with anti-TNFα, 
which will allow it to be further refined (item reduction) 
and its psychometric properties (validity, reproducibility, 
reliability) to be documented. The instrument will be then 
fully available for use in future clinical research studies or 
epidemiological studies to compare satisfaction with differ-
ent anti-TNFα treatments in CD, or to observe the evolution 
of satisfaction with medication when patients switch from 
corticosteroids to anti-TNFα.
Copyrights
The SPACE© questionnaire is protected by copyright 
with all rights reserved by Abbott. Do not use without 
  permission. For information on, or permission to use, 
the SPACE© questionnaire, please contact the Mapi 
Research Trust, 27 rue de la Villette, 69003 Lyon, France. 
Tel: +33 (0) 472 13 65 75; Email: trust@mapi.fr; website: 
www.mapi-trust.org.
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